DENTSPLY SIRONA Inc.

NasdaqGS:XRAY Stock Report

Market Cap: US$6.4b

DENTSPLY SIRONA Balance Sheet Health

Financial Health criteria checks 3/6

DENTSPLY SIRONA has a total shareholder equity of $3.3B and total debt of $2.1B, which brings its debt-to-equity ratio to 64.8%. Its total assets and total liabilities are $7.4B and $4.1B respectively. DENTSPLY SIRONA's EBIT is $289.0M making its interest coverage ratio 3.6. It has cash and short-term investments of $367.0M.

Key information

64.8%

Debt to equity ratio

US$2.14b

Debt

Interest coverage ratio3.6x
CashUS$367.00m
EquityUS$3.29b
Total liabilitiesUS$4.08b
Total assetsUS$7.37b

Recent financial health updates

Recent updates

Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?

Apr 22
Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?

There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues

Mar 10
There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues

Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden

Feb 16
Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden

DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward

Jan 29
DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate

Jan 11
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate

Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

Nov 25
Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively

Nov 06
These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively

Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture

Oct 15
Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture

An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued

Sep 18
An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued

DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet

Jul 31
DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet

The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

Jul 09
The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Jun 20
A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

Jun 02
When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel

May 15
Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel

The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

Apr 05
The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?

Mar 07
Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?

We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt

Nov 09
We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt

Dentsply Sirona names Glenn Coleman as new CFO

Sep 22

Dentsply Sirona hires Simon Campion as president, CEO

Aug 25

Dentsply Sirona receives noncompliance notice from Nasdaq

Aug 16

Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument

Jul 18

Dentsply Sirona Seems Unaffected By Management Reshuffles

May 02

Investors Will Want DENTSPLY SIRONA's (NASDAQ:XRAY) Growth In ROCE To Persist

Apr 29
Investors Will Want DENTSPLY SIRONA's (NASDAQ:XRAY) Growth In ROCE To Persist

DENTSPLY SIRONA (NASDAQ:XRAY) Seems To Use Debt Rather Sparingly

Mar 16
DENTSPLY SIRONA (NASDAQ:XRAY) Seems To Use Debt Rather Sparingly

Financial Position Analysis

Short Term Liabilities: XRAY's short term assets ($2.0B) exceed its short term liabilities ($1.4B).

Long Term Liabilities: XRAY's short term assets ($2.0B) do not cover its long term liabilities ($2.7B).


Debt to Equity History and Analysis

Debt Level: XRAY's net debt to equity ratio (53.7%) is considered high.

Reducing Debt: XRAY's debt to equity ratio has increased from 32.3% to 64.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable XRAY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: XRAY is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 2.8% per year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.